My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 8 451 / DOI: 10.3332/ecancer.2014.451

Policy

NHS reforms in England: the implications for chemotherapy commissioning

For oncology, one of the biggest effects of the reforms to the National Health Service (NHS) in England has been the designation of systemic anticancer treatments (other than hormonal agents) as a specialised service. This means that all decisions regarding the commissioning of chemotherapy are made at the national level via NHS England (NHSE), under expert guidance from the Chemotherapy Clinical Reference Group (CRG). Commissioning decisions will be based on several factors, not only clinical efficacy and cost/affordability, but also the ‘added value’ that a new treatment may offer in terms of patient outcomes, resource utilisation, and/or wider benefits to society. Oncology health-care professionals (HCPs) are in a position to affect cancer commissioning decisions in the reformed NHS, not only the small number who are members of the Chemotherapy CRG, but also as advisors to the Chemotherapy CRG via disease-specific consensus work, and through participation in the collection and reporting of real-life data on patient outcomes. With the emerging emphasis on both consensus work and outcomes data, a step change can also be expected in the relationship between HCPs and the pharmaceutical industry, including a strengthened role for non-promotional education, support for forums and consensus groups, and facilitation of the development, collection, and dissemination of findings from real-life practice. In addition, there will be an onus on the pharmaceutical industry to provide information on the implications that new products may have for service delivery and capacity and for meeting patients’ and society’s expectations. This information will need to be developed and delivered in a timely way, well in advance of the launch of a new product.

Keywords: Cancer Drugs Fund, Clinical Commissioning Groups, Clinical Reference Groups, NHS England, systemic anticancer treatment, value-based assessment

Categories:

Economics Medicines

Loading Article Metrics ... Please wait

Related articles

Special Issue: The cost of cancer care is not related to its outcomes

Abstract | Full Article | PDF Published: 28 Oct 2016 / DOI: 10.3332/ecancer.2016.687

Special Issue: Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology

Abstract | Full Article | PDF Published: 28 Oct 2016 / DOI: 10.3332/ecancer.2016.686

Special Issue: Health technology assessment and value: the cancer value label (CAVALA) methodology

Abstract | Full Article | PDF Published: 28 Oct 2016 / DOI: 10.3332/ecancer.2016.685

Special Issue: Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis

Abstract | Full Article | PDF Published: 28 Oct 2016 / DOI: 10.3332/ecancer.2016.684

Special Issue: Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation

Abstract | Full Article | PDF Published: 28 Oct 2016 / DOI: 10.3332/ecancer.2016.683



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence